ARTICLE | Company News
Serodus, Roche deal
December 13, 2010 8:00 AM UTC
Roche granted Serodus exclusive, worldwide rights to develop and commercialize RO1160367 ( SER101). Next quarter, Serodus plans to start a Phase II trial of the selective serotonin (5-HT4) receptor ...